Open AccessSingle‐Pill Therapy in the Treatment of Concomitant Hypertension and Dyslipidemia (The Amlodipine/Atorvastatin Gemini Study)
Author(s) -
Blank Roy,
LaSalle James,
Reeves Russell,
Maroni Jaman,
Tarasenko Lisa,
Sun Franklin
Publication year - 2005
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2005.04533.x
Subject(s) - dyslipidemia , amlodipine , medicine , atorvastatin , blood pressure , concomitant , pill , adverse effect , blood lipids , essential hypertension , cholesterol , pharmacology , obesity
The Gemini Study was a 14‐week, open‐label, noncomparative, office‐based, multicenter trial to evaluate single‐pill therapy in the treatment of concomitant hypertension and dyslipidemia. In addition to recommending lifestyle modifications, eight dosage strengths of amlodipine/atorvastatin single pill (5/10, 5/20, 5/40, 5/80,10/10,10/20,10/40, and 10/80 mg) were electively titrated to improve blood pressure and lipid control. A total of 1220 patients with uncontrolled hypertension at baseline received study medication. At baseline, mean blood pressure was 146.6/87.9 mm Hg and mean low‐density lipoprotein cholesterol concentration was 152.9 mg/dL. At study end, 57.7% of patients had achieved both their blood pressure and low‐density lipoprotein cholesterol goals (51.9% of patients with uncontrolled low‐density lipoprotein cholesterol at baseline). The mean dose of study medication at end point was amlodipine component 7.1 mg and atorvastatin component 26.2 mg. Fifty‐eight patients (4.8%) discontinued therapy due to adverse events. Single‐pill therapy is effective in reducing both blood pressure and lipid levels and in helping patients achieve goals for both hypertension and dyslipidemia.